Today
-3.76%
5 Days
+5.93%
1 Month
+19.41%
6 Months
+41.44%
Year to Date
+27.60%
1 Year
+48.34%
• Amgen shares dropped despite beating third-quarter revenue and earnings consensus estimates. • Legacy franchises face accelerating sales declines from biosimilar competition and patent expirations. • Management flagged rising fourth-quarter operating expenditures and increased capital investment requirements.
• Eli Lilly shares declined due to valuation sensitivity and competitive metabolic dynamics. • Institutional profit-taking and macroeconomic cross-asset flows exacerbated the recent pullback. • The company maintains strong fundamentals, with $65.18 billion in annual revenue.
• Gilead shares declined due to institutional profit-taking and technical consolidation after earnings. • Acquired research and development charges created headwinds for reported GAAP profitability. • Analysts maintain a buy rating with an average price target of $171.76.
• AbbVie exceeded consensus estimates and raised its full-year guidance. • Skyrizi and Rinvoq drove strong double-digit sales expansion. • Multiple Wall Street firms raised their price targets.
• Merck raised full-year guidance following strong financial results and global demand. • Late-stage pipeline progress reinforced confidence in the company's growth strategy. • Analysts assigned an average price target of $157.01 with Buy ratings.
• Johnson & Johnson reported positive clinical trial updates in MedTech and oncology portfolios. • The company exceeded quarterly earnings forecasts and reaffirmed its full-year earnings guidance. • Institutional stakeholders increased their positions amid favorable analyst ratings and technical buy signals.
Eli Lilly (LLY) Q3 2026 Earnings Call: Revenue Up 39%, Guidance Raised


| Shareholders | Proportion |
|---|---|
| Lilly Endowment, Inc. | 9.76% |
| Vanguard Capital Management, LLC | 5.67% |
| PNC Investments LLC | 5.43% |
| BlackRock Institutional Trust Company, N.A. | 4.44% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 46.65% |
| Investment Advisor/Hedge Fund | 19.18% |
| Foundation | 9.76% |
| Research Firm | 2.14% |
Related Instruments